CLL ARC 2018

Speakers

Keynote and Invited Speakers

The Organising Committee is pleased to announce the following confirmed Keynote and Invited Speakers:

 

Dr Jennifer R. Brown

Jennifer_BrownJennifer R. Brown, MD, PhD is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.   Dr. Brown completed a B.S. and M.S. simultaneously in molecular biophysics and biochemistry (MB&B) at Yale, graduating summa cum laude with distinction in MB&B.  She proceeded to Harvard Medical School where she received her MD and PhD in molecular genetics in 1998 and was awarded the James Tolbert Shipley Prize for research accomplishment in the graduating class.  She then served as an intern and resident in Internal Medicine at Massachusetts General Hospital followed by fellowship in Hematology and Medical Oncology at the Dana-Farber Cancer Institute. Dr. Brown joined the faculty of DFCI and Harvard Medical School in 2004, where she has an active clinical-translational research program in CLL. 

 Her particular interests include the development of novel targeted therapeutics for CLL, as well as the genomics of CLL. She has been instrumental in the clinical development of both idelalisib and ibrutinib, leading to their regulatory approvals in CLL. In the area of genomics she has been instrumental in the description of the somatic mutation profile of CLL, and is now particularly interested in the implementation of genomic technology in the clinic, including for prognosis and targeted therapy.  She also has a longstanding research interest and focus on the inherited predisposition to CLL. To date she has published over 150 papers in the scientific literature, predominantly in CLL. She is an active member of the CLL Research Consortium and serves on the Alliance Leukemia and Leukemia Correlative Science Committees as well as the NIH Cancer Biomarkers Study Section.  In 2014 she was the recipient of two awards from Dana-Farber Cancer Institute, the Clinical Innovation Award, as well as the George Canellos Award for Excellence in Clinical Investigation and Patient Care. She enjoys a worldwide reputation as a CLL expert and is in much demand as an international speaker.

 

Dr Kostas Stamatopoulos

Kostas Stamatopoulos 2Kostas Stamatopoulos is the Director of the Institute of Applied Biosciences at CERTH, the Center for Research and Technology Hellas, Thessaloniki, Greece. He also holds the positions of Visiting Professor in Lymphoid Tumor Biology at Uppsala University, Uppsala Sweden; and, Research Collaborator of the Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece. Dr. Stamatopoulos has published extensively about the immunobiology of lymphoid malignancies. He is Board member of ERIC, the European Research Initiative on CLL; founding member of the IMGT CLL-DB initiative and the IgCLL group, both operating under the auspices of ERIC; Board member of the Splenic Lymphoma Group; member of the Steering Group of the Euroclonality-NGS Consortium. His current research interests include: immunogenetics of human lymphoid malignancies; cell signaling; genetic diagnostics; precision medicine in cancer; and, patient empowerment in care.

Dr Kyle Crassini

Dr. Kyle Crassini completed his medical degree at the University of Sydney in 2012 with first class honours, during which he received the Deans Scholarship Award (2012), Graham Coupland Award (2010) and was awarded an RSL Scholarship to Fiji in 2009. He undertook his intern year and basic physician training at Royal North Shore Hospital in Sydney.

Currently Dr. Kyle Crassini is an advanced trainee in clinical and laboratory haematology at Royal Prince Alfred Hospital and is enrolled as a PhD candidate at the University of Sydney with Professor Stephen Mulligan. Dr. Crassini’s research focuses on aspects of immune dysfunction in CLL in the modern treatment era and on modeling the CLL tumor microenvironment to investigate novel therapeutic agents. Dr. Crassini’s research is supported by an NHMRC postgraduate scholarship.

A/Prof Erica Wood

Associate Professor Erica Wood is Head, Transfusion Research Unit, at Monash University in Melbourne, and a haematologist/transfusion medicine specialist at Monash Health and the Peter MacCallum Cancer Centre.

Erica is the President-elect of the International Society of Blood Transfusion, current President of the International Haemovigilance Network, past-President of the Australian/New Zealand Society of Blood Transfusion, and member of the WHO Expert Advisory Panel on blood safety.

Erica served as Chief Examiner (Haematology) for the Royal College of Pathologists of Australasia and chaired the Haematology Joint Specialist Advisory Committee. She is a founding member of the Victorian Blood Matters Program advisory committee, established to implement clinical guidelines and transfusion practice improvement in Victorian hospitals. She was awarded a Churchill Fellowship in 2014 for her work in patient blood management.

Erica’s group coordinates a number of major Australian/NZ registries and clinical trials. These include studies of immunoglobulin use in patients with haematologic malignancies, such as the RATIONAL trial (prophylactic oral antibiotics vs immunoglobulin) and the IMPROVE study of current immunoglobulin replacement practice in myeloma through the Myeloma and Related Diseases Registry.

Dr Bernard Hudson


A/Prof Dr Bernie Hudson is a specialist Clinical Microbiologist and Infectious Diseases Physician, who holds specialist qualifications in pathology (microbiology), internal medicine (infectious diseases), public health and tropical medicine. He also holds a position as Clinical Senior Lecturer in Infectious Diseases at Sydney University. He is also an Associate Professor in the School of Public Health, Tropical Medicine & Rehabilitation Sciences at James Cook University, Townsville Queensland. He is currently Director of Microbiology & Infectious Diseases, NSW Health Pathology, at Royal North Shore Hospital St Leonards Sydney Australia. He has worked in the field of clinical infectious diseases and clinical microbiology for over three decades, with significant involvement in prevention, diagnosis and management of infections in immunocompromised patients.

Dr Chan Cheah

Dr Cheah is a Haematologist and Clinical Researcher at Sir Charles Gairdner Hospital and the University of Western Australia (UWA). He graduated in Medicine from the UWA and completed post-graduate training at Fremantle Hospital, Peter MacCallum Cancer Centre and MD Anderson Cancer Center (Houston, Texas, USA).

He is the clinical lead for lymphoma at Sir Charles Gairdner Hospital and Director of the WA Lymphoma Centre of Research Excellence. He has authored >70 peer-reviewed publications, 6 book chapters, attracted >$3M in competitive grant funding and reviews for major journals in the field. He is passionate about improving access for Australian patients to the novel lymphoma treatments and training the next generation of lymphoma researchers.